FDA Commissioner Marty Makary resigned Tuesday, one day before he was set to testify before the Senate Appropriations Committee, after weeks of mounting pressure from pro-life leaders, Republican lawmakers, and HHS Secretary Robert F. Kennedy Jr., who a White House official said pushed for the departure.
Kyle Diamantis, the FDA's deputy commissioner for food, will step into the role as acting commissioner, Fox News Digital reported, citing a White House official. Kennedy posted on X that the search for a permanent replacement "is already underway, and we will move forward with urgency."
The resignation caps a turbulent tenure at the helm of the nation's food and drug regulator, a tenure defined, in the eyes of many conservatives, by Makary's handling of the abortion pill mifepristone, his approval of a new generic version of the drug, and what critics called a pattern of sidelining pro-life concerns inside the agency.
A White House official told Fox News Digital the resignation had to do with "process at the FDA" and not a specific issue. The official added there was "no bad blood" between the president and Makary.
President Trump, speaking to reporters as he departed the White House for a trip to China, offered praise but stopped short of explaining the circumstances:
"He's a great doctor and he was having some difficulty, but he's going to go on and he's going to do well."
Trump would not say whether he fired Makary or asked him to resign. Breitbart reported that Trump told reporters Makary was "going to be off" and that the deputy would take over temporarily.
The Wall Street Journal had reported Friday, citing three sources, that Trump had already signed off on a plan to fire Makary. Asked about it that day, Trump said, "I've been reading about it, but I know nothing about it."
By Tuesday, the president struck a warmer tone on Truth Social:
"I want to thank Dr. Marty Makary for having done a great job at the FDA. So much was accomplished under his leadership. He was a hard worker, who was respected by all, and will go on to have an outstanding career in Medicine. Kyle Diamantas, a very talented person, will be put in the Acting position."
The frustration from the pro-life movement was not subtle. Earlier in May, a Trump administration official told Fox News Digital bluntly what many inside the building were thinking:
"What a mess Makary turned out to be. The arrogance is stunning."
That official said Makary had signaled to "every pro-life advocate their concerns are an afterthought." Under Makary's leadership, the FDA left intact rules allowing mifepristone to be prescribed online and shipped through the mail, a policy that pro-life groups had expected the Trump administration to reverse. The agency also approved a new generic version of the pill last year.
Lila Rose, president of Live Action, had called on Trump and Kennedy to act before the resignation became public. She told Fox News Digital that the administration must "stop the mail order abortion scheme, and pull these child-killing drugs from the market." Makary's continued leadership of the agency, in her view, was incompatible with the movement's goals.
Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, went further. She told the Wall Street Journal earlier in May that "Trump is the problem" on abortion issues, and said candidates seeking her organization's $160 million in support for the midterms and 2028 presidential election would need to commit "to pro-life action at the national level."
That kind of direct challenge from a major conservative ally signals just how deep the rift had grown, not only over Makary, but over the broader question of whether the administration's health agencies were following through on campaign promises to the pro-life base.
Republican Missouri Sen. Josh Hawley told Fox News Digital he was "glad" to hear the news. His assessment of Makary's record was unsparing:
"He was terrible to the pro-life movement. He attempted to place pro-abortion lawyers in key positions. He not only slow-walked a safety review of the dangerous abortion drug mifepristone; he greenlit a new abortion drug that sends 11% of women to the emergency room."
Hawley added that "Makary's resignation is an opportunity for the FDA to reset and protect life." The senator's reference to a drug sending 11 percent of women to the emergency room was not further detailed in public reporting, and the specific drug he was referencing was not named.
The combination of Hawley's criticism and the pro-life movement's sustained campaign against Makary made clear that his position had become untenable, regardless of whether the White House wanted to frame the exit as amicable.
The man stepping into the acting role brings his own backstory. Just the News reported that Diamantis had previously served as the FDA's top food official, and that Makary's departure followed a turbulent 13-month tenure marked by disputes over abortion drugs, vape approvals, and the broader Make America Healthy Again agenda.
Diamantis also has a past in litigation that drew immediate scrutiny. White House spokesperson Kush Desai told Fox News Digital that Diamantis had once been assigned to represent Planned Parenthood as a junior legal associate, but walked away from the case on principle:
"Kyle Diamantas was a junior legal associate who was assigned to that case by his superiors. He expressed his objections to representing Planned Parenthood based on his personal convictions, and ultimately removed himself from the case."
The specific case was not identified. But the White House clearly wanted to get ahead of any suggestion that Diamantis was anything less than aligned with the administration's values on life issues.
Kennedy, in his X post, praised Diamantis directly, saying "his leadership has already delivered remarkable wins on the MAHA food agenda, and I have full confidence in his continued work."
Makary's exit is the latest in a string of senior personnel shakeups across the administration this year. Former Homeland Security Secretary Kristi Noem and former Attorney General Pam Bondi have also departed, each under different circumstances, but all contributing to a sense of churn at the highest levels of the executive branch.
The pattern is not limited to civilian agencies. The Pentagon has seen its own wave of forced departures, including the ouster of Navy Secretary John Phelan over a clash with Defense Secretary Pete Hegseth on shipbuilding priorities.
Kennedy, for his part, framed the transition in generous terms. In his post on X, he thanked Makary for taking on "entrenched interests" and said the outgoing commissioner "never lost sight of the American people we serve."
Whether that generosity reflected genuine gratitude or diplomatic courtesy is an open question. The White House official's acknowledgment that Kennedy pushed for the resignation suggests the relationship had run its course well before Tuesday's announcement.
The military side of the administration has seen similar dynamics play out. Hegseth's removal of Army Chief of Staff General Randy George followed a comparable pattern: internal friction, public praise, and a swift appointment of an acting replacement.
Several questions remain unanswered. The White House official's reference to "process at the FDA" as the reason for the departure was vague enough to cover almost anything, and specific enough to cover nothing. What that process failure looked like in practice, and whether it involved specific regulatory decisions or broader management concerns, was not explained.
Makary's scheduled testimony before the Senate Appropriations Committee on Wednesday, now presumably off the table, raises its own questions. What he was expected to discuss, and whether his resignation was timed to avoid that appearance, was not addressed by the White House.
The Washington Examiner reported that Makary had faced conflicts over vaping, abortion policy, and pharmaceutical approval decisions, creating pressure from the White House, GOP allies, and industry alike. That combination of forces, political, ideological, and commercial, made the FDA commissioner's chair one of the most contested seats in the administration.
The search for a permanent replacement now begins in earnest. For the pro-life movement, the test is straightforward: will the next commissioner treat their priorities as central to the agency's mission, or as an afterthought? The answer will say more about this administration's commitments than any farewell post on social media.
Across the government, the administration has shown a willingness to move quickly when officials fall out of step with the president's agenda, as the abrupt retirement of the Army's top general also made clear earlier this year.
Personnel is policy. The FDA just got a reminder.